GlassScriptPhysician profile
Lisa Keeling
NPI 1932460508
$3,423.63
in general payments reported to CMS, 2019-2025
26 companies · $882 in 2025
The $882 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $333 · 2021: $336 · 2022: $271 · 2023: $562 · 2024: $789 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,232.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $900.55 | 2019-2025 | |
| Novo Nordisk INC | $474.14 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Pfizer INC. | $379.92 | 2019-2025 | |
| Lilly USA, LLC | $373.97 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $279.48 | 2019-2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $154.08 | 2023-2025 | Arexvy, Boostrix, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.11 | 2019-2025 | Ofev |
| Janssen Pharmaceuticals, INC | $131.36 | 2020-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $67.23 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $64.12 | 2021-2024 | Vaqta, Gardasil 9, Vaxneuvance |
| Sanofi Pasteur INC. | $59.35 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.57 | 2020-2024 | Trintellix |
| Inspire Medical Systems, INC. | $48.25 | 2023-2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.95 | 2020-2024 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $32.16 | 2024-2025 | Qelbree |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $30.58 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.96 | 2024 | Caplyta |
| Inari Medical, INC. | $20.59 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amarin Pharma, INC. | $19.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.35 | 2024 | |
| Abbott Laboratories | $16.75 | 2025 | Proclaim |
| Ibsa Pharma INC. | $16.41 | 2023 | Tirosint, Licart |
| Idorsia Pharmaceuticals US INC | $16.29 | 2024 | Quviviq |
| Alnylam Pharmaceuticals INC. | $15.33 | 2025 | Givlaari |
| Adlon Therapeutics L.P. | $15.06 | 2020 | |
| Exact Sciences Corporation | $13.92 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Keeling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.